{"id":48201,"date":"2022-09-10T09:02:38","date_gmt":"2022-09-10T07:02:38","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/wugen-presents-preclinical-data-on-wu-nk-101-in-solid-tumor-models-at-the-european-society-for-medical-oncology-esmo-congress-2022\/"},"modified":"2022-09-10T09:02:38","modified_gmt":"2022-09-10T07:02:38","slug":"wugen-presents-preclinical-data-on-wu-nk-101-in-solid-tumor-models-at-the-european-society-for-medical-oncology-esmo-congress-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/wugen-presents-preclinical-data-on-wu-nk-101-in-solid-tumor-models-at-the-european-society-for-medical-oncology-esmo-congress-2022\/","title":{"rendered":"Wugen Presents Preclinical Data on WU-NK-101 in Solid Tumor Models at the European Society for Medical Oncology (ESMO) Congress 2022"},"content":{"rendered":"
\n

\n— WU-NK-101 exhibited enhanced metabolic fitness and adaptability, enabling superior resilience within the immunosuppressive solid tumor microenvironment and preserved cytotoxic function —<\/i>\n<\/p>\n

\n— WU-NK-101 demonstrated robust anti-tumor activity, tumor trafficking, and penetration further augmented by monoclonal antibodies (mAbs) —<\/i>\n<\/p>\n

\n— Data support the clinical development of WU-NK-101 for solid tumor indications —<\/i>\n<\/p>\n

ST. LOUIS & SAN DIEGO–(BUSINESS WIRE)–Wugen, Inc.<\/a>, a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today presented preclinical data on WU-NK-101, the company\u2019s lead memory natural killer (NK) cell therapy product, in a poster session at the European Society for Medical Oncology (ESMO) Congress 2022, taking place in Paris, France from September 9-13, 2022.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWe are pleased to present these data and build on the growing body of evidence validating our best-in-class memory NK cell platform,\u201d said Dan Kemp, Ph.D., President and Chief Executive Officer of Wugen. \u201cToday\u2019s findings are an important step forward as we continue to advance WU-NK-101 into clinical development for both solid tumors and acute myeloid leukemia (AML).\u201d\n<\/p>\n

\n\u201cWhile adoptive cell therapies have proven a powerful tool against hematological cancers, their application to solid tumors has historically been limited by restricted cell trafficking to tumors and the harsh tumor microenvironment (TME),\u201d added Sergio Rutella, M.D., Ph.D., FRCPath, FRSB, Professor of Cancer Immunotherapy at Nottingham Trent University and presenting author. \u201cThese findings are highly promising and suggest that memory NK cells can circumvent these challenges, with broad potential therapeutic applications for solid tumors.\u201d\n<\/p>\n

\nToday\u2019s presentation highlighted the following:\n<\/p>\n